Results 71 to 80 of about 98,807 (272)

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer [PDF]

, 2001
BACKGROUND: The incidence of lung cancer is declining following a drop in smoking rates, but it is still the leading cause of death from cancer in England and Wales, with about 30,000 deaths a year.
A. Clegg, N. Waugh, D. A. Scott, M. Sidhu, Waugh, N, Clegg, A. J., Scott, David A., Waugh, Norman, Clegg, A, Hewitson, P., Hewitson, P, Scott, D A, Sidhu, M, Sidhu, M. K., P. Hewitson   +14 more
core   +1 more source

Inactivation of XPF Sensitizes Cancer Cells to Gemcitabine

Journal of Nucleic Acids, 2019
Gemcitabine (2′, 2′-difluorodeoxycytidine; dFdC) is a deoxycytidine analog and is used primarily against pancreatic cancer. The cytotoxicity of gemcitabine is due to the inhibition of DNA replication.
Joseph W. George, Mika Bessho, Tadayoshi Bessho   +2 more
doaj   +1 more source

Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]

PLoS ONE, 2012
Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang, Wei-Peng Yong   +6 more
doaj   +1 more source

Chemoproteomic Identification of AKT2 as a Paclitaxel‐Binding Protein via C─C Bond‐Linked Probe PTX‐4 in Paclitaxel‐Resistant Breast Cancer

Advanced Science, EarlyView.
ABSTRACT Breast cancer remains one of the most prevalent malignancies among women, and taxane‐based chemotherapies such as paclitaxel and docetaxel are central to standard treatment regimens. However, drug resistance in breast cancer limits therapeutic efficacy and contributes to recurrence and metastasis.
Kai Wang, Yuqing Yuan, Wei Shen, Xiuxiu Yang, Xiaokang Wu, Haihua Zhou, Yi Hu, Qing Zhu   +7 more
wiley   +1 more source

Unveiling Lactylation: A Novel Frontier in Cancer Stemness and Therapy

Advanced Science, EarlyView.
Tumor metabolism and epigenetic regulation are intrinsically linked. This review highlights lactylation as a pivotal bridge connecting these processes, acting as an active epigenetic effector in cancer stemness. We delineate how lactylation orchestrates the cancer stem cell landscape and evaluate its regulatory networks.
Ting Li, Hongyu Gu, Chang Liu, Yuesheng Lv, Feifei Li, Liang Liang, Jia Yi, Xuanyi Wang, Yi Zhun Zhu, Chuan Xu   +9 more
wiley   +1 more source

H‑Gemcitabine: A New Gemcitabine Prodrug for Treating Cancer [PDF]

, 2016
In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine.
Abhinav P. Acharya (2002042), Seungjun Lee (2000281), Dongin Kim (2002045), Sungmun Lee (534990), Niren Murthy (1320648), Madhuri Dasari (2002039), Ross Molinaro (138224), Jeanne Rhea (2002036)   +7 more
core   +1 more source

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj  

RBM10 Deficiency Promotes Anti‐PD‐1 Resistance in LUAD via STING Alternative Splicing‐Driven CCL7 Signaling and Macrophage Polarization

Advanced Science, EarlyView.
RBM10 deficiency promotes anti‐PD‐1 resistance in lung adenocarcinoma by altering STING alternative splicing, which enhances CCL7 secretion and CCR2‐dependent M2 macrophage polarization. A positive feedback loop via mitochondrial transfer sustains this immunosuppression.
Weitong Gao, Ruqiong Wang, Bo An, Lishuang Qi, Zihan Jing, Xingmei Ren, Yang Zhou, Mingjun Xu, Jiaojiao Li, Jie Liu, Liying Wang, Gang Xu, Rou Li, Dexin Jia, Yan Yu   +14 more
wiley   +1 more source

Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207

Molecular Oncology, 2018
Gemcitabine serves as a first‐line chemotherapy agent for advanced pancreatic cancer (PC). However, the molecular basis by which gemcitabine exerts its effects is not well‐established, and the targeted genetic pathways remain unclear.
Lei You, Huanyu Wang, Gang Yang, Fangyu Zhao, Jingcheng Zhang, Ziwen Liu, Taiping Zhang, Zhiyong Liang, Changzheng Liu, Yupei Zhao   +9 more
doaj   +1 more source

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition

Neoplasia: An International Journal for Oncology Research, 2012
Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine.
Venkatasubbaiah A. Venkatesha, Leslie A. Parsels, Joshua D. Parsels, Lili Zhao, Sonya D. Zabludoff, Diane M. Simeone, Jonathan Maybaum, Theodore S. Lawrence, Meredith A. Morgan   +8 more
doaj   +1 more source